ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

CSL, Takeda and GC Biopharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

CSL×Takeda×GC Biopharma×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

CSLTakedaGC Biopharma
studies on the registry2681,75479
open to participants now18867
phase 3 studies under way6444
reach primary completion within a year4475
programswith a study of their own in two years11257

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseCSLTakedaGC Biopharma
Phase 100%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
00%
Phase 2

CSL: 3 of its 11 programs at phase 2

  1. VIT-2763phase 2
  2. anumigilimabphase 2
  3. hemopexin (human)phase 2
27%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

GC Biopharma: 4 of its 7 programs at phase 2

  1. GC4006Aphase 2
  2. gc1134aphase 2
  3. GC3111Bphase 2
  4. hm15421phase 2
57%
Phase 3

CSL: 4 of its 11 programs at phase 3

  1. CSL300phase 3
  2. Immunoglobulins, Intravenousphase 3
  3. Four-factor Prothrombin Complex Concentratephase 3
  4. lonoctocog alfaphase 3
36%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

GC Biopharma: 3 of its 7 programs at phase 3

  1. MG1111phase 3
  2. vaccination of GC3114Bphase 3
  3. idursulfase betaphase 3
43%
Approved, new studies

CSL: 4 of its 11 programs at approved, new studies

  1. Immunoglobulinsapproved, new study
  2. Hizentraapproved, new study
  3. alpha 1-Antitrypsinapproved, new study
  4. garadacimabapproved, new study
36%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
CSL3 readouts · 1 phase 3·····

CSL, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Four-factor Prothrombin Complex Concentratephase 3 · Apr 6 · NCT07094087
···

CSL, Aug ’27: 1 program whose next study reaches primary completion

  1. CSL300phase 3 · Aug 30 · NCT07619820
·

CSL, Oct ’27: 1 program whose next study reaches primary completion

  1. hemopexin (human)phase 2 · Oct 22 · NCT06699849
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
GC Biopharma2 readouts · 1 phase 3······

GC Biopharma, May ’27: 1 program whose next study reaches primary completion

  1. GC4006Aphase 2 · May 0 · NCT07728396
··

GC Biopharma, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MG1111phase 3 · Aug 0 · NCT07054099
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

CSL

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

GC Biopharma

New programs 1

Reached a new phase 1

  • GC4006Aphase 2 · Oct 21 · COVID-19

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionCSLTakedaGC Biopharma
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here

CSL in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 3 programs

  1. Immunoglobulins, Intravenousphase 3
  2. Immunoglobulinsapproved, new study
  3. Hizentraapproved, new study

Their studies: CSL’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Takeda in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 4 programs

  1. TAK-411phase 2
  2. Immunoglobulins, Intravenousapproved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

–
Primary Immunodeficiency Diseases2 of 3 · compare here

CSL in Primary Immunodeficiency Diseases: 3 programs

  1. Immunoglobulins, Intravenousphase 3
  2. Immunoglobulinsapproved, new study
  3. Hizentraapproved, new study

Their studies: CSL’s studies of Primary Immunodeficiency Diseases in search

Takeda in Primary Immunodeficiency Diseases: 4 programs

  1. Immunoglobulins, Intravenousapproved, new study
  2. TAK-664approved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Primary Immunodeficiency Diseases in search

–
Anemia, Sickle Cell2 of 3 · compare here

CSL in Anemia, Sickle Cell: 3 programs

  1. VIT-2763phase 2
  2. anumigilimabphase 2
  3. hemopexin (human)phase 2

Their studies: CSL’s studies of Anemia, Sickle Cell in search

Takeda in Anemia, Sickle Cell: 1 program

  1. apadamtase alfaphase 3

Their studies: Takeda’s studies of Anemia, Sickle Cell in search

–
Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here

CSL in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. Immunoglobulins, Intravenousphase 3
  2. Immunoglobulinsapproved, new study

Their studies: CSL’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

–
COVID-192 of 3 · compare here

CSL in COVID-19: 1 program

  1. anumigilimabphase 2

Their studies: CSL’s studies of COVID-19 in search

–

GC Biopharma in COVID-19: 1 program

  1. GC4006Aphase 2

Their studies: GC Biopharma’s studies of COVID-19 in search

Hemochromatosis2 of 3 · compare here

CSL in Hemochromatosis: 1 program

  1. VIT-2763phase 2

Their studies: CSL’s studies of Hemochromatosis in search

Takeda in Hemochromatosis: 1 program

  1. rusfertidephase 2

Their studies: Takeda’s studies of Hemochromatosis in search

–
Hemophilia A2 of 3 · compare here

CSL in Hemophilia A: 1 program

  1. lonoctocog alfaphase 3

Their studies: CSL’s studies of Hemophilia A in search

Takeda in Hemophilia A: 1 program

  1. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of Hemophilia A in search

–
Immunologic Deficiency Syndromes2 of 3 · compare here

CSL in Immunologic Deficiency Syndromes: 1 program

  1. Immunoglobulins, Intravenousphase 3

Their studies: CSL’s studies of Immunologic Deficiency Syndromes in search

Takeda in Immunologic Deficiency Syndromes: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Immunologic Deficiency Syndromes in search

–
Myasthenia Gravis2 of 3 · compare here

CSL in Myasthenia Gravis: 1 program

  1. Immunoglobulins, Intravenousphase 3

Their studies: CSL’s studies of Myasthenia Gravis in search

Takeda in Myasthenia Gravis: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Myasthenia Gravis in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetCSLTakedaGC Biopharma
F8lonoctocog alfaruleantihemophilic factor, human recombinantrule–
A target, or a pathogen for a vaccine, known for: CSL 3 of 11 · Takeda 12 of 25 · GC Biopharma 0 of 7 programs (15 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.